Drug Profile


Latest Information Update: 30 Nov 2015

Price : $50

At a glance

  • Originator Health Ever Bio-Tech
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 04 Nov 2015 Health Ever Biotech initiates enrolment in a phase II trial for Prostate cancer (Prevention) in Taiwan
  • 01 Oct 2014 Phase-II clinical trials in Prostate cancer (Prevention) in Taiwan (PO) (NCT02042807)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top